Elevated serum triiodothyronine (t3) in Ashkenazi Jewish prostate cancer patients carrying the I1307k allele of the APC (adenopolyposis coli) gene

Urologic Oncology: Seminars and Original Investigations

Volumn 21, Issue 2, 2003, Pages 101-104

  Lehrer, Steven ^a,b,c   Diamond, Edward J ^a,b   Stone, Nelson N ^a,b   Droller, Michael J ^a,b   Stock, Richard G ^a,b   Stone, Michelle ^a,b   Bajwa, Asghar ^a,b   Kornreich, Ruth ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

A denopolyposis coli gene; Ashkenazi Jews; Prostate cancer; Triiodothyronine (t3)

Indexed keywords

APC PROTEIN; LIOTHYRONINE;

ADULT; AGED; ALLELE; AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA ISOLATION; DOT HYBRIDIZATION; ETHNOLOGY; GENE AMPLIFICATION; GENE MUTATION; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE TEST; JEW; MALE; MITOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; BLOOD; GENETICS; MIDDLE AGED; MUTATION; PROSTATE TUMOR; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; ALLELES; GENES, APC; HUMANS; JEWS; MALE; MIDDLE AGED; MUTATION; PROSTATIC NEOPLASMS; TRIIODOTHYRONINE;

EID: 0041885002     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(02)00210-7     Document Type: Article

References (26)

1. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics 1994. CA 1994;44:7-26.
2. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Int Med 1993;118:793-803.
3. Giovannucci E, Tosteson TD, Speizer FE, Ascherio A, Vessey MP, Colditz GA. A retrospective cohort study of vasectomy and prostate cancer in US men. JAMA 1993;269:878-82.
4. Whittemore AS, Wu AH, Kolonel LN, et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 1995;141:732-40.
5. Ozen M, Navone NM, Multani AS, et al. Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. Cancer Genet Cytogenet 1998;106:105-9.
6. Cunningham JM, Shan A, Wick MJ, et al. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 1996;56:4475-82.
7. Ewing CM, Ru N, Morton RA, et al. Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with reexpression of alpha-catenin and restoration of E-cadherin function. Cancer Res 1995;55:4813-7.
8. Degeorges A, Hoffschir F, Cussenot O, et al. Recurrent cytogenetic alterations of prostate carcinoma and amplification of c-myc or epidermal growth factor receptor in subclones of immortalized PNT1 human prostate epithelial cell line. Int J Cancer 1995;62:724-31.
9. Woodage T, King SM, Wacholder S, et al. The APC I1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet 1998;20:62-5.
10. Gao X, Porter AT, Honn KV. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications. Adv Exp Med Biol 1997;407:41-53.
11. Phillips SM, Morton DG, Lee SJ, Wallace DM, Neoptolemos JP. Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Br J Urol 1994;73:390-5.
12. Lehrer S, McCurdy LD, Stock RG, Kornreich R, Stone NN, Eng C. Body mass, age, and the APC I1307K allele in Ashkenazi Jewish prostate cancer patients. Cancer Genet Cytogenet 2000;122:131-3.
13. Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997;17:79-83.
14. Petrukhin L, Dangel J, Vanderveer L, et al. The I1307K APC mutation does not predispose to colorectal cancer in Jewish Ashkenazi breast and breast-ovarian cancer kindreds. Cancer Res 1997;57:5480-4.
15. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC -/- colon carcinoma. Science 1997;275:1784-7.
16. Rubinfeld B, Robbins P, El Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997;275:1790-2.
17. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-90.
18. Suzuki H, Aida S, Akimoto S, Igarashi T, Yatani R, Shimazaki J. State of adenomatous polyposis coli gene and ras oncogenes in Japanese prostate cancer. Jpn J Cancer Res 1994;85:847-52.
19. Watanabe M, Kakiuchi H, Kato H, et al. APC gene mutations in human prostate cancer. Jpn J Clin Oncol 1996;26:77-81.
20. Hedlund TE, Miller GJ. A serum-free defined medium capable of supporting growth of four established human prostatic carcinoma cell lines. Prostate 1994;24:221-8.
21. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd edition. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989.
22. Zumoff B, Levin J, Strain GW, et al. Abnormal levels of plasma hormones in men with prostate cancer: evidence toward a "two-disease" theory. Prostate 1982;3:579-88.
23. Mellemgaard A, From G, Jorgensen T, Johansen C, Olsen JH, Perrild H. Cancer risk in individuals with benign thyroid disorders. Thyroid 1998;8:751-4.
24. Fenton PA, Clarke SE, Owen W, Hibbert J, Hodgson SV. Cribriform variant papillary thyroid cancer: a characteristic of familial adenomatous polyposis. Thyroid 2001;11:193-7.
25. Cetta F, Curia MC, Montalto G, et al. Thyroid carcinoma usually occurs in patients with familial adenomatous polyposis in the absence of biallelic inactivation of the adenomatous polyposis coli gene. J Clin Endocrinol Metab 2001;86:427-32.
26. Zhang S, Hsieh ML, Zhu W, Klee GG, Tindall DJ, Young CY. Interactive effects of triiodothyronine and androgens on prostate cell growth and gene expression. Endocrinology 1999;140:1665-71.